Celyad Oncology SA
XBRU:CYAD

Watchlist Manager
Celyad Oncology SA Logo
Celyad Oncology SA
XBRU:CYAD
Watchlist
Price: 0.65 EUR -2.99% Market Closed
Market Cap: 14.7m EUR
Have any thoughts about
Celyad Oncology SA?
Write Note

Celyad Oncology SA
Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Celyad Oncology SA
Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
Celyad Oncology SA
XBRU:CYAD
Operating Expenses
-€7.8m
CAGR 3-Years
20%
CAGR 5-Years
26%
CAGR 10-Years
N/A
M
MDxHealth SA
NASDAQ:MDXH
Operating Expenses
-$111.2m
CAGR 3-Years
-47%
CAGR 5-Years
-21%
CAGR 10-Years
-15%
Galapagos NV
AEX:GLPG
Operating Expenses
-€698.5m
CAGR 3-Years
0%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Oxurion NV
XBRU:OXUR
Operating Expenses
-€12.1m
CAGR 3-Years
26%
CAGR 5-Years
22%
CAGR 10-Years
N/A
No Stocks Found

Celyad Oncology SA
Glance View

Market Cap
14.7m EUR
Industry
Biotechnology

Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 88 full-time employees. The company went IPO on 2013-07-05. The firm is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The firm develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The firm's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). The company also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).

CYAD Intrinsic Value
0.03 EUR
Overvaluation 96%
Intrinsic Value
Price

See Also

What is Celyad Oncology SA's Operating Expenses?
Operating Expenses
-7.8m EUR

Based on the financial report for Jun 30, 2024, Celyad Oncology SA's Operating Expenses amounts to -7.8m EUR.

What is Celyad Oncology SA's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
26%

Over the last year, the Operating Expenses growth was 74%. The average annual Operating Expenses growth rates for Celyad Oncology SA have been 20% over the past three years , 26% over the past five years .

Back to Top